- Joined
- Feb 2, 2016
- Messages
- 34,002
- Reaction score
- 0
Those were very small trials and the highlights were around one or two miracle cases, with most cases unresponsive. The research is ongoing but they haven't had any kind of meaningful readout in the interim. That's sort of standard though, these studies take a very long time to set up, and you need to follow patients for long enough to get a line on various survival metrics (overall survival, invasive disease free surivival, progression free survival being common items on the Kaplan Meier). The fact that a single center study didn't readout in two years means little.
Meanwhile, you're seeing car-t therapies gaining traction with regulators, and everybody's trying to bring a checkpoint inhibitor to market. These are essentially tests of the same mechanism of action, without using live virus treatment.
VICE reported extremely high success rates. Do you have something more current that raises questions there?
Edit: I think I'm remembering you providing this to me before.